Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 323

1.

MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93.

Montanini L, Lasagna L, Barili V, Jonstrup SP, Murgia A, Pazzaglia L, Conti A, Novello C, Kjems J, Perris R, Benassi MS.

Cell Oncol (Dordr). 2012 Feb;35(1):29-41. doi: 10.1007/s13402-011-0059-z. Epub 2011 Sep 30.

PMID:
21959981
2.

Immune response to Mycobacterium tuberculosis infection in the parietal pleura of patients with tuberculous pleurisy.

Caramori G, Lasagna L, Casalini AG, Adcock IM, Casolari P, Contoli M, Tafuro F, Padovani A, Chung KF, Barnes PJ, Papi A, Rindi G, Bertorelli G.

PLoS One. 2011;6(7):e22637. doi: 10.1371/journal.pone.0022637. Epub 2011 Jul 28.

3.

Do "placebo responders" exist?

Kaptchuk TJ, Kelley JM, Deykin A, Wayne PM, Lasagna LC, Epstein IO, Kirsch I, Wechsler ME.

Contemp Clin Trials. 2008 Jul;29(4):587-95. doi: 10.1016/j.cct.2008.02.002. Epub 2008 Feb 23. Review.

PMID:
18378192
4.

Investigating placebo effects in irritable bowel syndrome: a novel research design.

Conboy LA, Wasserman RH, Jacobson EE, Davis RB, Legedza AT, Park M, Rivers AL, Morey EB, Nam BH, Lasagna L, Kirsch I, Lembo AJ, Kaptchuk TJ, Kerr CE.

Contemp Clin Trials. 2006 Apr;27(2):123-34. Epub 2006 Jan 19.

PMID:
16427366
5.

Statistical uncertainty.

Lasagna L.

Clin Ther. 2002 Apr;24(4):471-2. No abstract available.

PMID:
12017393
6.

Demystifying central review boards: current options and future directions.

Levine RJ, Lasagna L.

IRB. 2000 Nov-Dec;22(6):1-9. No abstract available.

PMID:
11883483
7.

The mind and morality of the doctor. II. The physician and the macrocosm. 1965.

Lasagna L.

Yale J Biol Med. 2000 Jan-Dec;73(1-6):389-400; discussion 400-2. No abstract available.

PMID:
11765962
9.

Balancing risks versus benefits in drug therapy decisions.

Lasagna L.

Clin Ther. 1998;20 Suppl C:C72-9. Review.

PMID:
9915092
10.

Issues facing the new FDA commissioner.

Lasagna L, Kaitin KI.

Science. 1998 Nov 13;282(5392):1263. No abstract available.

11.
12.

The dose-response model for dioxin.

Byrd DM 3rd, Allen DO, Beamer RL, Besch HR Jr, Bylund DB, Doull J, Fleming WW, Fries A, Guengerich FP, Hornbrook R, Lasagna L, Lum BK, Michaelis EK, Morgan ET, Poland A, Rozman KK, Smith JB, Swanson HI, Waddell W, Wilson JD.

Risk Anal. 1998 Feb;18(1):1-2. No abstract available.

PMID:
9556441
13.

Defining our future work.

Lasagna L.

Pharmacoeconomics. 1998;14 Suppl 1:143-6. No abstract available.

PMID:
10186476
14.

Issues in pharmaceutical lotteries: the case of interferon beta-1b.

Manocchia M, Lasagna L.

Clin Pharmacol Ther. 1997 Sep;62(3):241-7. No abstract available.

PMID:
9333099
15.

Recent trends in drug development.

Lasagna L.

Publ Am Inst Hist Pharm. 1997;16:217-22. No abstract available.

PMID:
11619896
17.
18.

Defining our future work.

Lasagna L.

Pharmacoeconomics. 1996;10 Suppl 2:139-41. No abstract available.

PMID:
10163431
19.

Over-the-counter hypnotics and chronic insomnia in the elderly.

Lasagna L.

J Clin Psychopharmacol. 1995 Dec;15(6):383-6. Review. No abstract available.

PMID:
8748426
20.

Availability of anticancer drugs in the United States, Europe, and Japan from 1960 through 1991.

Brown JS, Bienz-Tadmor B, Lasagna L.

Clin Pharmacol Ther. 1995 Sep;58(3):243-56. No abstract available.

PMID:
7554697
21.

Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective.

Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L.

Clin Pharmacol Ther. 1995 Jul;58(1):108-17.

PMID:
7628177
22.

The Helsinki Declaration: timeless guide or irrelevant anachronism?

Lasagna L.

J Clin Psychopharmacol. 1995 Apr;15(2):96-8. No abstract available.

PMID:
7782494
23.

Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.

DiMasi JA, Hansen RW, Grabowski HG, Lasagna L.

Pharmacoeconomics. 1995 Feb;7(2):152-69.

PMID:
10155302
24.

A white paper on the appropriateness of proposals by the FDA to modify labeling of benzodiazepine sedative-hypnotics.

Lasagna L, Shader RI.

J Clin Pharmacol. 1994 Aug;34(8):812-5. No abstract available.

PMID:
7962668
25.

New drug development in the United States from 1963 to 1992.

DiMasi JA, Seibring MA, Lasagna L.

Clin Pharmacol Ther. 1994 Jun;55(6):609-22. No abstract available.

PMID:
8004878
26.

Over-the-counter niacin.

Lasagna L.

JAMA. 1994 Mar 2;271(9):709-10. No abstract available.

PMID:
8309037
27.

The new drug approvals of 1990, 1991, and 1992: trends in drug development.

Kaitin KI, Manocchia M, Seibring M, Lasagna L.

J Clin Pharmacol. 1994 Feb;34(2):120-7.

PMID:
8163711
28.

The role of the research-based pharmaceutical industry in medical progress in the United States.

Kaitin KI, Bryant NR, Lasagna L.

J Clin Pharmacol. 1993 May;33(5):412-7.

PMID:
8331197
29.

Macrocyclic molecules and their pharmacological applications.

Lasagna L.

Eur J Rheumatol Inflamm. 1993;12(4):3-5. No abstract available.

PMID:
7805702
30.

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo.

Weintraub M, Sundaresan PR, Madan M, Schuster B, Balder A, Lasagna L, Cox C.

Clin Pharmacol Ther. 1992 May;51(5):586-94.

PMID:
1587072
31.

Biopharmaceuticals and conventional drugs: clinical success rates.

Bienz-Tadmor B, Dicerbo PA, Tadmor G, Lasagna L.

Biotechnology (N Y). 1992 May;10(5):521-5. No abstract available.

PMID:
1368232
32.

Pharmaceutical regulation in the European Community: barriers to single market integration.

Orzack LH, Kaitin KI, Lasagna L.

J Health Polit Policy Law. 1992 Winter;17(4):847-68.

PMID:
1299692
33.

New drug development in the United States from 1963 to 1990.

DiMasi JA, Bryant NR, Lasagna L.

Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):471-86. No abstract available.

PMID:
1934860
34.

Cost of innovation in the pharmaceutical industry.

DiMasi JA, Hansen RW, Grabowski HG, Lasagna L.

J Health Econ. 1991 Jul;10(2):107-42.

PMID:
10113009
35.

New indications for already-approved drugs: an analysis of regulatory review times.

DiMasi JA, Kaitin KI, Fernandez-Carol C, Lasagna L.

J Clin Pharmacol. 1991 Mar;31(3):205-15.

PMID:
2019661
36.

The new drug approvals of 1987, 1988, and 1989: trends in drug development.

Kaitin KI, DiCerbo PA, Lasagna L.

J Clin Pharmacol. 1991 Feb;31(2):116-22.

PMID:
2010558
37.

Mortal decisions: What Kind of Life and Who Lives? Who Dies?

Lasagna L.

Sciences (New York). 1991 Jan-Feb;31(1):43-6. No abstract available.

PMID:
11659327
38.

Advocacy: a new role for cancer patients.

Lasagna L.

Cancer Invest. 1991;9(5):609-10. No abstract available.

PMID:
1933495
39.

The Catastrophic Care Act: lessons to be learned.

Wastila LJ, Richard BW, Dicerbo PA, Lasagna L.

Am Pharm. 1990 Jun;NS30(6):22-3. No abstract available.

PMID:
2368664
40.

Are drug benefits also part of pharmacoepidemiology?

Lasagna L.

J Clin Epidemiol. 1990;43(9):849-50. No abstract available.

PMID:
2213073
41.

Approvable letters in the FDA new drug approval process.

Richard BW, Ulcickas M, Lasagna L.

J Clin Pharmacol. 1989 Aug;29(8):680-4. No abstract available.

PMID:
2778089
42.

The drug lag: an update of new drug introductions in the United States and in the United Kingdom, 1977 through 1987.

Kaitin KI, Mattison N, Northington FK, Lasagna L.

Clin Pharmacol Ther. 1989 Aug;46(2):121-38.

PMID:
2758722
43.

Congress, the FDA, and new drug development: before and after 1962.

Lasagna L.

Perspect Biol Med. 1989 Spring;32(3):322-43. No abstract available.

PMID:
2657639
44.

Involuntary self-intoxication with triazolam.

Lasagna L.

Psychiatr J Univ Ott. 1988 Sep;13(3):175. No abstract available.

PMID:
3054983
45.

Anorectic drugs: drug policy making at the state level.

Richard BW, Lasagna L.

J Clin Pharmacol. 1988 May;28(5):396-400. Review.

PMID:
3292600
46.

New drug development in the United States, 1963 through 1984.

Mattison N, Trimble AG, Lasagna L.

Clin Pharmacol Ther. 1988 Mar;43(3):290-301.

PMID:
3278822
47.

Over-the-counter analgesics: rational developments in the future.

Lasagna L.

Agents Actions Suppl. 1988;25:69-76. No abstract available.

PMID:
3265592
48.

Benefit-risk ratio of agonist-antagonist analgesics.

Lasagna L.

Drug Alcohol Depend. 1987 Dec;20(4):385-93. Review.

PMID:
2894291
49.

Trends in drug development: the 1985-86 new drug approvals.

Kaitin KI, Richard BW, Lasagna L.

J Clin Pharmacol. 1987 Aug;27(8):542-8.

PMID:
3655005
50.

Supplemental Content

Loading ...
Support Center